Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy

Di Li,Tianqi Su,Lili Ma,Feng Yin,Weiguo Xu,Jianxun Ding,Zigang Li
DOI: https://doi.org/10.1016/j.ejmech.2020.112367
IF: 7.088
2020-08-01
European Journal of Medicinal Chemistry
Abstract:<p>Polymer-drug conjugates synthesized by binding therapeutic agents to functional polymers have long been a mainstay of prodrugs, while the slow drug release, insufficient efficacy of a single drug, and low selectivity hampers the clinical translation. By rational prodrug design, a targeted dual-acidity-labile polysaccharide-di-drugs conjugate was synthesized by one-pot simultaneous Schiff base and boronic esterification reactions between oxidized dextran (Dex-CHO) and cyclo-(Arg-Gly-Asp-D-Phe-Lys) (c (RGDfK)), doxorubicin (DOX), and bortezomib (BTZ). The polysaccharide-di-drugs conjugate (Dex-<em>g</em>-(DOX + BTZ)/cRGD) self-assembled into micelle with a diameter at around 80 nm and released the drugs simultaneously triggered by the acidic condition. Dex-<em>g</em>-(DOX + BTZ)/cRGD specifically recognized and entered the cancer cells through the RGD-α<sub>v</sub>β<sub>3</sub> integrin interplay, selectively released DOX and BTZ in the acidic intracellular microenvironment, and efficiently inhibited the cell proliferation <em>in vitro</em>. More importantly, Dex-DOX/BTZ/cRGD showed higher intratumoral accumulation and better antitumor efficacy <em>in vivo</em> compared with free drugs and non-targeted control prodrug Dex-<em>g</em>-(DOX + BTZ). The findings indicated that Dex-<em>g</em>-(DOX + BTZ)/cRGD provided a facile strategy to develop smart polymer-multi-drugs conjugates for targeted cancer chemotherapy.</p>
chemistry, medicinal
What problem does this paper attempt to address?
The problem this paper attempts to address is: In cancer chemotherapy, single-drug treatments often fail to achieve ideal therapeutic effects due to issues such as slow drug release, insufficient efficacy, and low selectivity. To overcome these problems, researchers have designed a dual acid-sensitive polysaccharide-dual drug conjugate (Dex-g-(DOX+BTZ)/cRGD). Through rational design, two anticancer drugs (Doxorubicin DOX and Bortezomib BTZ) are linked to a functionalized polysaccharide (oxidized dextran Dex-CHO), and cyclic arginine-glycine-aspartic acid (c(RGDfK)) is introduced as a targeting ligand to achieve selective recognition and efficient endocytosis of tumor cells. This conjugate can rapidly release drugs under acidic conditions, thereby improving anticancer efficacy. Additionally, the c(RGDfK)-mediated targeting enhances drug accumulation at the tumor site and reduces toxicity to normal tissues. Experimental results show that Dex-g-(DOX+BTZ)/cRGD exhibits higher antitumor effects and lower systemic toxicity both in vitro and in vivo, demonstrating significant clinical application potential.